Bioxcel Therapeutics shares rise 3.19% premarket after LB Pharmaceuticals strengthens board with new appointments.

Bioxcel Therapeutics, Inc. rose 3.19% in premarket trading. LB Pharmaceuticals, Inc. announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors, effective as of the pricing of its initial public offering on September 10, 2025. The company believes that Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company advances its lead product candidate, LB-102, into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression.